Dataset consists of 107 full clinical study reports (CSRs) of published and unpublished randomized, placebo-controlled clinical trials of two neuraminidase inhibitors. A systematic review of the CSRs and other regulatory documents was conducted to determine the potential benefits and harms of oseltamivir (Tamiflu) and zanamivir (Relenza). Outcome measures included time to first alleviation of symptoms, influenza outcomes, complications, admissions to hospital, and adverse events in the intention to treat population. Completeness of relevant parts of the CSRs was determined via an extraction form based on the CONSORT statement checklist. Authors have provided the full set of clinical study reports for both medications provided to the Cochrane collaboration by Roche, GlaxoSmithKline, and the European Medicines Agency (EMA) for use in the systematic review of these neuraminidase inhibitors for treating/preventing influenza in healthy adults and children. A guest post on the "Dryad News and Views" site regarding the dataset of clinical study reports and the resulting Cochrane systematic review is available at: https://blog.datadryad.org/2014/04/17/tamiflu-data/
Dataset comprises hospitalization rates for opioid injection-related skin and soft-tissue infections (O-SSTI) correlated with changes in the price and purity of heroin for the years 1993 through 2010, inclusive. Data is derived from the Healthcare Cost and Utilization Project (HCUP) Nationwide Inpatient Sample (NIS) and the Drug Enforcement Administration (DEA) System to Retrieve Information from Drug Evidence (STRIDE) databases for 27 Metropolitan Statistical Areas (MSAs).
This dataset was generated from a qualitative, exploratory study to understand how the Baltimore Specialized Prostitution Diversion Program (SPD) operated and was experienced by those working and participating in it. Qualitative data included observations of participants during their interactions with the court and SPD staff as well as interviews with twenty-one SPD clients. Administrative program data was collected in 2010 on 616 arrestees and included demographic information, self-assessment for areas of need, and participants’ goals. Administrative court data collected by SPD staff was also examined for 221 eligible participants and included court dates, weekly attendance, and program completion. The semi-structured interview guide allowed participant input with questions centered on their understanding and experience of the program, what impeded or facilitated their participation and engagement with the program, and general recommendations.
Dataset is comprised of heroin overdose-related and prescription opioid overdose-related hospitalization rates for the years 2000 through 2014. Data is derived from the Healthcare Cost and Utilization Project (HCUP) Nationwide Inpatient Sample (NIS). Included are rates by census region and division with separate rates for age and race.
This dataset is the result of a phase 3, randomized, double-blind, placebo-controlled efficacy trial of a single dose live oral cholera vaccine. PXVX0200 was developed to rapidly confer protection to humanitarian relief workers and other travelers visiting cholera-endemic areas as well as residents in regions experiencing outbreaks. Existing licensed vaccines require 2 or 3 (children) doses weeks apart. The trial consisted of 3 groups of volunteers each of which were randomly split into receiving either the PXVX0200 vaccine or a placebo. One group was challenged with virulent V. cholera O1 El Tor Inaba strain N16961 inoculum 10 days post-vaccination. A second group was challenged 3 months post-vaccination, while individuals in the third group remained unchallenged. A total of 197 volunteers participated in the trial. This dataset includes demographics and clinical and immunology measures from the 3 study sites: University of Maryland, Baltimore School of Medicine, Cincinnati Children’s Hospital Medical Center, Ohio, and the Vaccine Testing Center, University of Vermont College of Medicine. (National clinical trial registry number: NCT01895855; Research funded by: PaxVax, Inc.)
This study investigated the association of age with CD4+ cell counts of HIV patients receiving antiretroviral treatment (ART) over a 4 year period. Data were collected from 126,672 previously treatment-naïve patients in 4 Sub-Saharan African nations. The baseline CD4+ count was measured at onset of ART and at 6-month intervals thereafter. The predictor variable was the age at initiation of therapy with ages grouped in five 10-year ranges: 20-29, 30-39, 40-49, 50-59, and 60 and over. The following 8 baseline covariates were also noted: sex, WHO stage, functional status, active TB infection, active cryptococcal disease, active P. jiroveci pneumonia, other active opportunistic infections, and ART regimen. The resulting dataset includes 466,482 repeated CD4+ count measurements with demographic and other patient-related characteristics.
In 2015 the World Health Organization (WHO) eliminated CD4 restrictions for initiating antiretroviral therapy (ART) for people living with HIV (PLHIV) in developing countries. However, the success of therapy is also dependent upon additional health and demographic characteristics of HIV patients at the time they enroll in care. This study investigated pre-ART (time between enrollment and initiation of ART) factors associated with transition to therapy. Data was compiled from a review of 195,011 records of ART-naïve adults enrolled in HIV care and treatment facilities supported by AIDSRelief in Kenya and Tanzania. The outcome variable was transition out of pre-ART care by one of 4 mutually exclusive modes: started ART, died before ART initiation, lost to follow-up (LTFU), and transferred to another facility. The following baseline covariates were analyzed for their relevance to the mode of transition: sex, age at enrollment, CD4 count at enrollment, presence of tuberculosis at enrollment, presence of cryptococcal disease at enrollment, presence of other active opportunistic infections, and year of enrollment in care. The dataset includes demographic data and clinical measures.
This dataset is the result of a qualitative study exploring the impact on child care providers of recent changes in government policies such as the 2014 reauthorization of the Child Care Development Block Grant and the increasing number of state-funded pre-kindergarten programs. Although there is much research on the benefits of quality care for children, and some research on the struggles of parents seeking high quality care, few elicit the perspective of this crucial work force. Six focus groups were conducted with a total of 49 providers. Two groups each, one with center-based providers and one with home-based providers, were held in an urban, suburban, and rural location. Focus group data were supplemented with data from interviews with six rural providers, for a total study sample of 55. All interviews and focus groups were transcribed verbatim and analyzed using a constant comparative method and coding for emergent and sensitizing concepts
Idiopathic pulmonary fibrosis (IPF) produces scarring in the peripheral and basilar regions of the lung with macroscopically normal-appearing tissue in the central and apical areas. This study involved comparing transcriptomic profiles of the latter with transcriptomes of scarred IPF and healthy control lung tissues. The primary goal of the research was to elucidate the pathobiology of the disease in its earliest stages. Tissue samples were taken from lung explants of 3 IPF patients and healthy lung tissue from 3 transplant donors. Dataset includes 10 sequence reads from macroscopically normal-appearing areas and 8 from scarred regions from IPF lungs, and an additional 8 from the normal control tissue for a total of 26 samples. 1 supplementary PDF and 7 supplementary datasets in Excel are available at: http://dx.doi.org/10.1016/j.cellimm.2018.01.002
This dataset is the result of an investigation of caregivers’ management and treatment preferences for their ADHD child. From January 2013 through March 2015 a total of 184 caregivers of children 4 to 14 years of age were recruited from primary care, pediatric outpatient clinics, and support organizations in Maryland. The study explored caregiver variability and priorities when considering medication, change in management options over time, and preference for different treatment attributes. Data were collected using Best-Worst scaling and the Vanderbilt ADHD Diagnostic Parent Rating Scale (VADPRS). This dataset consists of caregiver and child demographic information, child diagnoses and treatment characteristics data, and caregiver preferences with regard to medication and observed and desired improvements in their child’s ADHD.